Crescent Grove Advisors LLC acquired a new position in shares of Exact Sciences Corporation (NASDAQ:EXAS) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 4,250 shares of the medical research company’s stock, valued at approximately $200,000.

Several other hedge funds have also recently added to or reduced their stakes in EXAS. Prudential Financial Inc. increased its holdings in shares of Exact Sciences Corporation by 3.0% during the 1st quarter. Prudential Financial Inc. now owns 11,141 shares of the medical research company’s stock worth $263,000 after buying an additional 320 shares during the last quarter. Teachers Advisors LLC increased its holdings in shares of Exact Sciences Corporation by 4.7% during the 1st quarter. Teachers Advisors LLC now owns 183,485 shares of the medical research company’s stock worth $4,334,000 after buying an additional 8,221 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Exact Sciences Corporation during the 1st quarter worth $8,298,000. BlackRock Inc. increased its holdings in shares of Exact Sciences Corporation by 45,816.0% during the 1st quarter. BlackRock Inc. now owns 6,804,297 shares of the medical research company’s stock worth $160,718,000 after buying an additional 6,789,478 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of Exact Sciences Corporation by 15.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 483,849 shares of the medical research company’s stock worth $11,429,000 after buying an additional 65,619 shares during the last quarter. Institutional investors and hedge funds own 85.65% of the company’s stock.

In other news, insider Graham Peter Lidgard sold 45,775 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $41.49, for a total transaction of $1,899,204.75. Following the transaction, the insider now owns 288,952 shares of the company’s stock, valued at $11,988,618.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP D Scott Coward sold 29,115 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the transaction, the senior vice president now directly owns 64,991 shares in the company, valued at approximately $3,064,975.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 277,373 shares of company stock valued at $12,635,570. 4.00% of the stock is currently owned by corporate insiders.

A number of research firms have recently commented on EXAS. Leerink Swann restated an “outperform” rating and set a $50.00 price objective (up from $45.00) on shares of Exact Sciences Corporation in a report on Thursday, September 21st. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 price target (up from $45.00) on shares of Exact Sciences Corporation in a research report on Tuesday, October 3rd. BidaskClub raised shares of Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. BTIG Research reaffirmed a “buy” rating and set a $45.00 price target (up from $35.00) on shares of Exact Sciences Corporation in a research report on Monday, July 17th. Finally, Zacks Investment Research raised shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $51.00 price target for the company in a research report on Tuesday, September 26th. Eight analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $49.98.

Exact Sciences Corporation (NASDAQ:EXAS) traded up $1.19 during trading hours on Monday, reaching $60.37. 1,352,200 shares of the company’s stock were exchanged, compared to its average volume of 2,562,707. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $63.60.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. The company had revenue of $72.60 million during the quarter, compared to analysts’ expectations of $65.03 million. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. The firm’s revenue for the quarter was up 158.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.36) EPS. sell-side analysts expect that Exact Sciences Corporation will post -1.14 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2017/11/13/crescent-grove-advisors-llc-invests-200000-in-exact-sciences-corporation-exas.html.

Exact Sciences Corporation Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.